Casdin Capital to Invest in Fluidigm

Paul, Weiss is advising Casdin Capital, LLC, in its $250 million investment, alongside Viking Global Investors LP, in Fluidigm Corporation. Fluidigm is a developer, manufacturer and marketer of health and disease technology intended to accelerate the development of more effective therapies for cancer, immunology and immunotherapy, among others. The investment will significantly advance Fluidigm’s organic and inorganic high-growth initiatives, optimize its cost structure, and expand its relationships with customers and other companies in the life sciences industry. The transaction is expected to close in the first quarter of 2022, subject to customary closing conditions. Upon closing of the investment, Fluidigm will change its name to Standard BioTools Inc.

The Paul, Weiss team includes, among others, corporate partners Krishna Veeraraghavan and John Kennedy, and counsel Oliver Board and David Sobel; executive compensation partner Jean McLoughlin; tax partner Robert Holo; intellectual property partner Jonathan Ashtor and counsel Michael Kurzer; litigation partners Geoffrey Chepiga and Liza Velazquez, and counsel Peter Jaffe and Rachel Fiorill; and antitrust counsel Yuni Sobel and Marta Kelly.